VGN-R08b
/ Shanghai Vitalgen BioPharma
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
May 23, 2026
A Phase I/II Clinical Study to Evaluate the Safety and Efficacy of VGN-R08b in Patients With Type III Gaucher's Disease
(clinicaltrials.gov)
- P1/2 | N=12 | Not yet recruiting | Sponsor: Shanghai Vitalgen BioPharma Co., Ltd.
New P1/2 trial • Gaucher Disease • Genetic Disorders • Metabolic Disorders • Type 1 Gaucher Disease • GBA1
February 18, 2026
A Trial to Evaluate Safety and Efficacy of a Product Named VGN-R08b in Parkinson's Disease Patients With GBA1 Mutations
(clinicaltrials.gov)
- P1/2 | N=17 | Not yet recruiting | Sponsor: Shanghai Vitalgen BioPharma Co., Ltd.
New P1/2 trial • CNS Disorders • Movement Disorders • Parkinson's Disease • GBA1
1 to 2
Of
2
Go to page
1